several other organic acidemias and amino acid catabolism disorders in which FAB-MS/MS has been shown to be of diagnostic utility. We are also presenting the results of our work on automation of the technique and its application in the quantification of acylcarnitines and amino acids. Samples. Blood spots used in this study were collected over a period of about 9 mo from patients referred to the Inborn Errors of Metabolism Unit at the King Faisal Specialist Hospital and Research Centre, Riyadh. Three spots of heparinized blood (75 p L each) were spotted on Schleicher & Schiill filter paper (S&S 903; Dassel, Germany), allowed to dry at room temperature for a few hours or overnight, and stored in polypropylene bags at room temperature until analysis.
METHODS
Unless otherwise noted, the data to be presented here were from new patients that were diagnosed initially by MS/MS analysis of blood before any treatment was carried out. When applicable, the diagnosis was confirmed by urine organic acid and/or plasma amino acid analyses by standard methods, and in some cases by enzyme assays.
Blood sample preparation. Two 3116-inch circles from each blood spot (-13 pL) were punched out, using a standard hole punch, into 1.5-mL polypropylene microcentrifuge tubes (3) . The samples were then extracted by shaking for 30 min in 400 p L of methanol or acetonitrile containing known amounts of the stable isotope-labeled internal standards. The tubes were then centrifuged at 14,000 rpm for 10 min. The supernatants were transferred to 1.1-mL glass vials with conical shaped bottoms (1.1-CTVG vials; obtained from Chromacol Limited; Welwyn Garden City, UK) and evaporated to dryness using a gentle stream of nitrogen. To the residues, 250 p L of butanolic HC1 was added (which was prepared by saturating dry nbutanol with HCl gas for 30 min). The vials were capped, vortexed, and heated at 65OC for 20 min. The resulting mixtures were again dried, and each residue was finally reconstituted in 150 p L of acetonitrilelwater (4:l vol/vol). The resulting solutions were transferred to 0.3-mL autosampler vials (03-CVG vials; obtained from Chromacol Limited), in preparation for MSIMS analysis.
MS. ESI-MS/MS was carried out on a Fisons Instruments
(Altrincham, UK) VG Quattro, triple quadrupole mass spectrometer, equipped with a Jasco model PU-980 HPLC pump and a Jasco model AS-950 autosampler, fitted with a 20-pL sample loop (Jasco International Co. Ltd., Tokyo, Japan). Argon was used as the collision gas at a pressure of 2.5 to 3.5 mTorr, and the collision energy was set to 25 eV. The ion source temperature was maintained at 70°C.
For acylcarnitine profiles, precursor ion scans of the peak at m/z 85 were monitored in the range m/z 250-500. For amino acid profiling, two neutral loss scan functions were used, one for neutral loss of 102 D, and the other for neutral loss of 119 D (4) . After a solvent delay time of 0.3 rnin from the time of sample injection, the three consecutive scan functions were carried out sequentially using a scan speed of one scan every 2 s for all functions. Each of the three scan functions was active, in the order listed above, during each of the following time periods (postsolvent delay): 0.0-0.7 min, 0.7-1.2 min, and 1.2-1.7 min.
The resolution of MS1 was adjusted in the precursor-ion mode, such that the acylcarnitine peaks were approximately 1.3 D wide at 15% height. This gave good sensitivity and allowed the peak detection and centering algorithm to discern peaks separated by only 1 D. The resolution of MS2 was set in the daughter-ion mode by observing the daughters of m/z 260 in the range m/z 80-90. Mass 260 corresponds to the molecular ions (M+) for both, the butyl ester of acetylcarnitine and the dibutyl ester of glutamic acid. Under CID conditions, the first produces a major fragment at m/z 135, whereas the latter produces a major fragment at miz 84. ' To minimize any interference from glutamate in the acetylcarnitine signal, the resolution parameters were adjusted to give a valley depth between masses 84 and 85 which was approximately 10% of the height of mass 84; and to give this resolution linearly throughout the mass range used for all scan functions.
For routine analysis, the data were acquired in the multichannel analysis mode, where all data collected during a particular scan function is recorded as a single summed analog data spectrum. As the individual scan intensities are not recorded, chromatograms cannot be obtained. In this mode, most of the noise is averaged out resulting in a significant improvement in the signal to noise ratio of the spectra. The storage of only summed spectral profiles also dramatically reduces space occupied by each patient's data file on the computer's hard disk.
For development work toward automation, signal intensity chromatograms were needed; therefore the data were acquired using the "MCB" data capture mode. 111 this mode, the spectral profile data from every scan is recorded, enabling the construction of both mass and total ion chromatograms; thereby allowing examination of interinjection resolution. To obtain spectra of good signal-to-noise quality for postrun analysis, it is essential to sum or average all the individual spectra recorded for each sample. Since only an "averaging" algorithm is currently available, these combined spectra yielded somewhat lower numerical intensities, but nevertheless equal signal-to-noise quality, when compared with those acquired by "summing" in the multichannel analysis mode.
Data processing. A macro was used for processing the MS/MS data. This program, written using the Microsoft Visual Basic program, automates key strokes in the VG Quattro Masslynx software. The operator is required to select the files to be processed by appending their names to the macro's processing table from the sample data directory. For each file, the macro sequentially selects and processes the spectrum corresponding to each scan function. The analog data are smoothed using a Savitzky-Golay algorithm (provided in the Masslynx software), and the smoothed spectrum is printed. The macro then centroids and hcight measures the smoothed data, creating and printing a numerical list of peak positions on the mass scale and their height intcnsities. This process takes 2.5 min for the three scan functions of each file, using a DECpc 486D2LP personal computer.
Automation of sample introduction. In initial work, manual injections were made using a Rheodyne injector model 7125. In latter work, toward automation of sample introduction, the injcctor port no. 4 on the autosampler was connected directly via a Rheodyne fcrrule to a fused silica tube (VG part no. 6028620; 75-ym inside diameter; about 65 cm long). Thc fused silica tube was connected through a specially drilled double-cnded vespel ferrule and a zcro dead volume fitting to a 34 gauge stainless steel tube (0.009 outside diameter; 0.005 inside diameter) inside the ESI probe. The length of the silica tubing was kept to a minimum to shorten the time it takes for the sample to reach the ion source. This time is termed "solvent delay time" and in our case was about 0.3 min at a flow rate of 20 pL/min. Nitrogen was used as both nebulizing gas and drying gas at a flow rate of 10 L/h for nebulization, and a flow of 200 L/h for drying. Maximizing the flow of the nebulizing gas is important for optimum spraying. A low nebulizing rate results in accumulation of a tiny amount of the injected sample on the bottom of the probe tip, causing carryover and decreased sensitivity problems. The mobile phase used for most experiments was acctonitrilclwater (65:35 vol/vol) at a flow rate of 20 pL/min without splitting. The autosampler was programmed to inject a volume of 22 p L of the sample every 3 min, with one flush cycle of the mobile phase before and after each injection.
Quantitative analysis of acylcarnitines and amino acids. Calibration curves were established for three acylcarnitines (acetylcarnitine, C,; octanoylcarnitine, C,; and palmitoylcarnitinc, C,,), and also for amino acids; alanine (Ala), leucine (Leu), and phenylalaninc (Phe) in control blood. A volume of 150 p L of blood was spotted on filter paper and allowed to dry. This whole spot was taken in a tube and extracted as before with 7.5 p L of methanol. Aliquots of this extract (100 pL; equivalent to 2 p L of blood) were taken. To each of these extracts were added 500 p L of the intcrnal standards solution containing the deuterated acylcarnitines (C,, 0.15 nmol; C,, 0.030 nmol; C,,, 0.0625 nmol) and the deutrated amino acids (Ala, Leu, Phc; 1.25 nmol of each). To the same extracts were also added incrcasing amounts of the unlabeled acylcarnitines and amino acids. The resulting solutions wcre vortexed and then evaporated to dryness. The residues were derivatized with butanolic HCl, and the procedure completed as described above (under blood sample preparation). The final injection mixtures were analyzed by automated ESI-MS/MS.
To examine the intra-and inter-day variation of the method, aliquots of 300 p L of blood from a known case of methylmalonic acidemia and a control blood sample were spotted on filter paper and allowed to dry. The whole spot in each case was extracted in 7.5 p L of methanol containing the labeled internal standards as described above. These extracts were dried and treated with 3.0 p L of butanolic HCI, and the procedure completed as described above. The final dried residues were rcconstituted in 3.0 p L of acetonitrile/water (4:l). Eight injections of each sample were made on each of d 2, 4, and 6. The ratios of measured absolute heights for each of acetylcarnitine, propionylcarnitine, palmitoylcarnitine, alanine, leucine, and phenylalanine, to their respective internal standard were calculated after MSIMS data processing, and the coefficient of variation intra-day and inter-day were determined.
RESULTS AND DISCUSSION

Acylcarnitine Profiling
The butyl esters of acylcarnitines arc well suited for analysis by positive-ion ESI-MS since they already carry a positive charge and accordingly, no additives are needed in the mobile phase. As such, they are detected as their respective molecular ions. Upon CID, these butyl esters yield a common fragment ion at m/z 85 corresponding to +CH,-CH=CH-COOH. This fragment results from the loss of elements of both (CH,),N and C,H, and the side chain acyl group as RCOOH. The precursor ion spectra thereby obtained show the molecular ion species corresponding to the butylated acylcarnitines in the sample.
Fatty acid oxidation defects. The acylcarnitine profile of a control blood sample is shown in Figurc 1A . The profile is essentially very similar to those produced by FAB-MS/MS (1-3). Acylcarnitine profiles from cases with fatty acid oxidation disorders are shown in Figure 1 , B, C, and D. The acylcarnitine profile shown in Figure 1B was obtained from a 20-d-old patient with GA type 2. The profile showed general elevation of the C, to C,, acylcarnitines. This diagnosis was supported by GCIMS urine organic acid analysis which showed significantly elevated dicarboxylic acids, including ethylmalonic, glutaric, adipic, and suberic acid. Isovalerylglycine and isobutrylglycine were also elevatcd (data not shown).
The acylcarnitine profile shown in Figure 1C is for a case of medium-chain acyl-CoA dehydrogenase deficiency in an American child, from whom a blood spot on an original Guthrie card was kindly provided by Dr. Piero Rinaldo (Yale University). The profile showed significant elevations in the C,, C,:,, C,, and C ,,:, species that are characteristic of this disorder. This diagnosis had been previously established by GCIMS urine analysis of acylglycines and by molecular analysis (7) .
The acylcarnitine profile shown in Figure I D represents a case of either long-chain or very long-chain acyl-CoA dehydrogenase deficiency from a 2-mo-old Saudi patient. Irlitial tandem MS analysis showed elevation of the C,,:, and C,,:, acylcarnitine species. Further investigation of this patient was carried out by carnitine loading for 24 h that resulted in a significant increase in C,,:, and C,,:, in addition to the C,, species. However, fasting for 8 h resulted in an even more prominent increase in the same species (data in Fig. ID) . A very similar FAB-MSIMS acylcarnitine profile was published carlier by Millington et al. (3) . Enzyme and molecular characterization of our patient is in progress.
Branched chain amino acid disorders. Abnormal profiles from cases affected with disorders of branched-chain amino acid catabolism are shown in Figure 2, A, 3 , C , and D. The acylcarnitine profile in Figure 2A is for a case of isovaleric acidemia. The profile showcd a very prominent ion at m/z 302 corresponding to isovalerylcarnitine. This preliminary diagno- sis was further confirmed by GCIMS urine organic acid analysis (data not shown).
The acylcarnitine profile in Figure 2B was obtained from a blood sample of a 1-y-old girl which was sent to our laboratory with no prior diagnosis. The acylcarnitine data suggested a possible diagnosis of P-ketothiolase deficiency due to the presence of prominent ions consistent with tiglylcarnitine (m/z 300) and 2-methyl-3-hydroxybutyrylcarnitine (mlz 318). The GC/MS analysis of urine organic acids confirmed the MS/MS results by the finding of excessive amounts of 2-methyl-3-hydroxybutyric acid (1793 mmol/mol creatinine; normal range is 3-72) and tiglylglycine (not quantified).
The profile shown in Figure 2C was obtained from a blood sample from a 1-mo-old Saudi girl. The acylcarnitine data suggested a possible diagnosis of HMG. The spectrum showed an ion at m/z 402 consistent with 3-methylglutarylcarnitine and a more prominent ion at m/z 318 presumably corresponding to 3-hydroxyisovalerylcarnitine. The ion at m/z 402, although not abundant, is strongly suggestive of HMG, because it has not been observed in blood of normal patients, or in other organic   1 1 1i4, , ,, , ,,,, , , , , , 7; , , , ,, ,318, , ~ , , , , , , acidemia cases diagnosed by this technique (1) . In four cases, HMG was diagnosed by tandem MS and was later confirmed by GC/MS urine organic acid analysis and enzyme assay in fibroblasts as previously described (8, 9). Figure 2 0 shows a typical acylcarnitine profile observed in patients with GA type 1. The spectrum was apparently normal except for the appearance of an ion at m/z 388 corresponding to glutarylcarnitine. It is this ion which suggests GA type 1, as it is not normally observed, except in cases of GA type 2, where several additional ions are elevated (see above). These data were supported by G U M S analysis of urine, which showed abnormal amounts of glutaric acid (2685 mmol/mol creatinine; normal, <2) as well as 3-hydroxyglutaric acid (211 mmol/mol creatinine; normal, 0-3) (8).
Amino Acid Profiling
ESI-MS/MS was applied to the ana1:ysis of amino acids after extraction from blood spots and derivatization to butyl esters. The butylated derivatives fall into two groups. With the exception of six of the amino acids (these being asparagine, glutamine, arginine, citrulline, lysine, and ornithine), the butylated amino acid species detected by this technique give a common "neutral loss" of 102 D, upon CID fragmentation. This corresponds to the loss of butylformate from their protonated molecular ions. It is noteworthy to mention that glycine produces a very weak signal and can be easily missed. The above mentioned six amino acids lose ammonia first, followed by butylformate, resulting in a total neutral loss of 119 D. Therefore, to get a more complete picture of the amino acids in the sample, two constant neutral loss scan functions were used, scanning for losses of 102 and 119 D, generating a separate profile for each scan function.
Amino acid disorders. A typical normal amino acid profile obtained by scanning for a neutral loss of 102 D is shown in Figure 3A . Abnormal profiles from cases affected with amino acid catabolism disorders are shown in Figures 3 and 4 . The amino acid profile shown in Figure 3B is characterized by a very prominent ion at m/z 222 corresponding to protonated molecular ion of butylated phenylalanine, and a very high ratio of phenylalanine to tyrosine (MH+ = 238), estimated to be about 18. These results were clearly consistent with a diagnosis of PKU (4) .
The profile in Figure 3C showed a very prominent ion at m/z 188 corresponding to leucine/isoleucine, a finding suggestive ' I " MSUD of maple syrup urine disease. The profile in Figure 3 0 was obtained from the blood sample of a 6-y-old female Saudi patient previously diagnosed as suffering from homocystinuria due to cystathionine P-synthetase deficiency. The enzyme assay showed <1% of normal activity. Accordingly, the amino acid profile showed a very prominent ion at mlz 206 corresponding to the butyl derivative of methionine, an amino acid that is normally very low or undetectable by this method in normal blood. Figure 4A shows an abnormal profile from the blood sample of a Saudi girl clinically suspected to have tyrosinemia type 1. The profile showed an abundant ion at mlz 238 corresponding to the butyl derivative of tyrosine, which agreed with the clinical observations. These data were further supported by the detection of a significant elevation of succinylacetone in the patient's urine by GC/MS analysis. A very similar profile was obtained from the blood sample of a 28-y-old Saudi man, previously diagnosed clinically and biochemically (plasma HPLC for amino acids) as suffering from tyrosinemia type 2.
Obviously, additional investigations, using other methods, are needed to distinguish the two types of tyrosinemia and whether either of these disorders is the true underlying cause for the elevation in tyrosine level.
In Figure 4B the prominence of the ion at m/z 186 that corresponds to the butyl derivative of pyroglutamic acid (5-oxoproline) suggested a possible diagnosis of pyroglutamic respectively. The first is for a known case of PKU, whereas the latter is for a control blood sample. It is clearly apparent in both examples that there is no carryover from one peak to the next. The same absence of carryover was observed for all the other abnormal samples injected in this sequence.
To date, the largest number of samples injected in one automatic sequence was 200 samples, over a 10-h period. Theoretically, 480 samples can be analyzed in a 24-h period; however, further work is needed to determine whether the system can actually handle such a large sample throughput every day without loss of sensitivity and to determine the appropriate source cleaning intervals.
Quantification and Reproducibility
In the initial development work, no quantification was carried out. The addition of the internal standards to the blood sample served as an indicator for recovery, and a standard solution containing these species was used to tune the mass spectrometer. In a latter stage of this study, determinations were carried out to examine the quantitative merits of the technique and its reproducibility. Calibration curves were linear in the range 0.5-50 ninol/pL of blood for acetylcarnitine (2 = 0.996), for octanoylcarnitine (2 = 0.995) and for palmitoylcarnitine (2 = 0.996). The calibration curves were linear for alanine (r2 = 0.992, range of 5-500 nmollpL of blood), leucine (r2 = 0.996; range of 5-500 nmol/pL), and for phenylalanine (r2 = 0.997; range of 5-800 nmol1pL). These results demonstrate the utility of the technique in quantifying both acylcarnitines and amino acids at levels well below normal, as well as for significantly elevated levels. Therefore, the method can clearly distinguish between normal and abnormal cases.
The precision of the assay was examined by repeated injections (n = 8) of one abnormal case (methylmalonic acidemia) and one normal sample. The results were excellent except for one of six analytes. Coefficients of variation percent were as follows (intra-day; inter-day): For the methylmalonic acidemia sample, acetylcarnitine (2.51; 3.02), propionylcarnitine (3.81; 3.81), palmitoylcarnitine (5.11; 5.57), alanine (22.03; 24.76), leucine (6.90; 7.12), and phenylalanine (4.11; 5.08). The results for the normal sample were very much the same or better than for the abnormal sample (data not shown). We feel that the high variation for alanine is due to the poor signal response for this compound and its deutrated analog, on an equimolar basis, relative to that for leucine and phenylalanine. In consequence, the signal to noise ratio for the amount of deuterated alanine currently added, is too low to give consistent ratio measurements. This can possibly be corrected by increasing the concentration of deutrated alanine in the internal standard mixture. A study is underway to determine the effects of long-term storage of spotted blood samples on the quality of the data.
In summary, the ESI-MS/MS system proved to be highly reliable. There was not a single breakdown in 9 mo of operation, and the ESI ion source was cleaned only once a month; a process that takes less than 30 min. The method described was found to be specific, accurate, and can easily discern normal from abnormal results. The profiles for extracted samples showed excellent reproducibility when samples were repeatedly analyzed on the same day, or at a latter time.
ESI-MSIMS is proven by our studies to be a primary tool for the diagnosis of about 20 different organic acid and amino acid catabolism disorders. In the last 9 mo we have analyzed approximately 2000 blood samples, diagnosed 52 new cases, and confirmed the diagnosis of another 75 previously known cases. The relatively large number of cases found in the last 9 mo reflects the high incidence of organic acid and amino acid disorders in Saudi Arabia, which is probably due to the relatively high level of consanguinity, because most of the diseases cluster in certain tribes (13). The most common diseases detected in this study were methylmalonic acidemia, propionic acidemia, PKU, maple syrup urine disease, HMG, GA type 1, and P-ketothiolase deficiency, in decreasing order. We believe that the successful automation of sample introduction achieved here should bring closer the possibility for developing "broad spectrum" neonatal screening programs for inborn errors of metabolism.
